Immuron Ltd (ASX: IMC) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Immuron Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $25.06 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 227.80 million
Earnings per share -0.020
Dividend per share N/A
Year To Date Return 10.00%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Immuron Ltd (ASX: IMC)
Latest News

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Why the Immuron (ASX:IMC) share price rocketed another 17% today

The biotech company is experiencing another healthy share jump today.

Read more »

a man raises his fists to the air in joyous celebration while learning some exciting good news via his computer screen in an office setting.
Healthcare Shares

Here’s why the Immuron (ASX:IMC) share price is rocketing 31% today

The company's shares are one of the best performers on the ASX today.

Read more »

Photo of a group of Imagion scientists cheering while working in a lab. as the Imagion share price skyrockets today on positive study results
Healthcare Shares

Immuron (ASX:IMC) share price surges 11% on COVID-19 treatment data

New research suggests the company's drug might be able to treat COVID-19

Read more »

A woman kicks a giant COVID-19 molecule, indicating positive share price movement for biotech companies
Healthcare Shares

Why the Immuron (ASX:IMC) share price is surging 8% higher

The Immuron Ltd (ASX: IMC) share price is surging 8% today after providing an update on its drug candidate, IMM124E.…

Read more »

woman in lab coat conducting testing representing biotech
Share Market News

Why the Immuron (ASX:IMC) share price fell today

The Immuron (ASX:IMC) share price closed lower today following the company's recently released earnings report. Here's the run down.

Read more »

A happy businessman pointing up, inidicating a rise in share price
Share Market News

Why the Immuron (ASX:IMC) share price is rocketing up 10% today

The Immuron Limited (ASX: IMC) share price is surging today following a research agreement with Monash University for combating COVID-19.

Read more »

Young girl wearing a suit and tie with rocket wings looks to the sky representing the highest traded stocks today
Share Market News

Why the Immuron (ASX:IMC) share price is rocketing 18% higher today

The Immuron share price is soaring higher today, up 18% in afternoon trading. We take a look at the company's…

Read more »

Buy stocks
Share Market News

Afterpay and Immuron were among the most traded shares on the ASX last week

Afterpay Ltd (ASX:APT) and Openpay Group Ltd (ASX:OPY) shares were among the most traded shares on the ASX last week. Here's…

Read more »

IMC ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Immuron Ltd

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

IMC Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
16 May 2022 $0.11 $0.01 9.52% 64,348 $0.11 $0.11 $0.11
13 May 2022 $0.11 $-0.01 -9.09% 70,650 $0.11 $0.11 $0.11
12 May 2022 $0.11 $0.00 0.00% 445,192 $0.12 $0.12 $0.11
11 May 2022 $0.11 $0.01 10.20% 496,155 $0.10 $0.11 $0.10
10 May 2022 $0.10 $-0.01 -9.09% 2,219,480 $0.11 $0.11 $0.10
09 May 2022 $0.11 $0.01 9.52% 48,433 $0.12 $0.12 $0.11
06 May 2022 $0.11 $0.00 0.00% 157,421 $0.11 $0.11 $0.11
05 May 2022 $0.11 $-0.01 -9.09% 460,269 $0.11 $0.11 $0.11
04 May 2022 $0.11 $-0.01 -8.70% 565,625 $0.11 $0.11 $0.11
03 May 2022 $0.12 $0.00 0.00% 69,218 $0.12 $0.12 $0.12
02 May 2022 $0.12 $0.00 0.00% 163,577 $0.12 $0.12 $0.11
29 Apr 2022 $0.12 $0.00 0.00% 142,849 $0.12 $0.12 $0.12
28 Apr 2022 $0.12 $-0.01 -8.00% 233,198 $0.12 $0.13 $0.12
27 Apr 2022 $0.13 $0.01 8.70% 1,197,144 $0.12 $0.13 $0.12
26 Apr 2022 $0.12 $0.00 0.00% 20,000 $0.12 $0.12 $0.12
22 Apr 2022 $0.12 $0.01 9.09% 109,653 $0.11 $0.12 $0.11
21 Apr 2022 $0.11 $-0.01 -8.70% 510,804 $0.12 $0.12 $0.11
20 Apr 2022 $0.12 $0.00 0.00% 119,037 $0.12 $0.12 $0.11

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr Roger Aston Non-Executive ChairmanNon-Executive Director May 2012
Dr Aston has more than 20 years' experience in the pharmaceutical and biotechnology industries. Dr Aston was previously the chief executive officer and a director of Mayne Pharma Group Limited (ASX: MYX). Prior to his position at Mayne Pharma, some of his previous positions have included chief executive officer of Peptech Limited (ASX: PTD), director of Cambridge Antibody Technology Limited (LSE: CAT and NASDAQ: CATG) and chairman of Bio Focus Plc (formerly: Cambridge Drug Discovery Limited). Dr Aston was also founder and chief executive officer of Biokine Technology Ltd (UK) prior to its acquisition by the Peptech Group. Dr Aston was also a director of pSivida Ltd. During the past 20 years of his career, Dr Aston has been closely involved in the development of many pharmaceutical and biotechnology companies. He has experience including negotiating global licence agreements, overseeing product registration activities with the FDA, the establishment and implementation of guidelines and operating procedures for manufacturing and clinical trials, overseeing manufacturing of human and veterinary products, private and public fund raising activities and the introduction of corporate governance procedures. He is a member of the Risk committee.
Mr Paul Brennan Non-Executive Director Mar 2022
Mr Brennan has experience in the health system through his clinical background and experience in commercialisation of technology, company governance, strategic planning and international marketing with various multinational companies. Mr Brennan was Chief Executive Officer (CEO) of PolyNovo Limited (ASX:PNV) for 7 years from 2015 to 2021. Prior to this Mr Brennan was Marketing Director Australia and New Zealand and Sales Director New Zealand for Smith & Nephew Healthcare for 6 years.
Mr Daniel Pollock Non-Executive Director Oct 2012
Mr Pollock is a sole practitioner in his own legal firm based in Melbourne which operates internationally and specialises in commercial law. Further, he is executive director and co-owner of Great Accommodation Pty Ltd, a property management business operating in Victoria. Mr Pollock has had historical involvement as a seed investor and board member of a number of small unlisted companies. The most recent of these was an e-pharmacy company where he was heavily involved in its commercial growth and ultimate sale to a large listed health services company. He is chair of risk committee.
Mr Stephen Anastasiou Non-Executive Director May 2013
Mr Anastasiou has over 20 years experience in general management, marketing and strategic planning within the healthcare industry. His experience incorporates medical diagnostics, pharmaceuticals, hospital, dental and over-the-counter products, with companies including the international pharmaceutical company Bristol-Myers Squibb (NYSE: BMY). While working with KPMG Peat Marwick as a management consultant, Mr Anastasiou has previously led project teams in a diverse range of market development and strategic planning projects in both the public and private sector. He is also a director and shareholder of a number of unlisted private companies, covering a variety of industry sectors that include healthcare and funds management. Mr Anastasiou's companies have participated in several corporate transactions involving business units and brands of multinational and Australian companies.
Mr Ravi Savarirayan Non-Executive Director Apr 2017
Prof Savarirayan has been a consultant clinical geneticist at the Victorian Clinical Genetics Services since August 1999, as well as professor and research group leader of skeletal biology and disease at the Murdoch Children's Research Institute since September 2000. Prof Savarirayan is a founding member of the Skeletal Dysplasia Management Consortium since January 2011 and has been the chair of the specialist advisory committee in clinical genetics at the Royal Australasian College of Physicians since February 2009. He was president of the International Skeletal Dysplasia Society from July 2009 to June 2011 and has been an invited member of several international working committees on constitutional diseases of bone. Prof. Savarirayan's primary research focus is on inherited disorders of the skeleton causing short stature, arthritis and osteoporosis and he leads numerous clinical therapy trials for these conditions. He has published over 180 peer-reviewed articles, collaborating with peers from over 30 countries. He has been on the editorial board of Human Mutation since January 2009, European Journal of Human Genetics since July 2007, American Journal of Medical Genetics since December 2011 and the Journal of Medical Genetics since June 2005. He was recently named one of the "Brilliant Minds" of the Murdoch Children's Research Institute over the past 30 years.
Mr Phillip Hains Chief Financial OfficerCompany Secretary Apr 2013
-
Dr Jerry Kanellos Chief Executive Officer Mar 2020
-
Jerry Kanellos Chief Executive Officer
-
Phillip Hains Chief Financial OfficerCompany Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 98,045,283 43.14%
Authentics Australia Pty Ltd <Authentics Australia A/C> 7,000,000 3.08%
Grandlodge Pty Ltd 4,931,682 2.17%
Dr Russell Kay Hancock 3,000,000 1.32%
Mr Stephen Anastasiou & Mrs Andria Anastasiou <Anastasiou Family S/F A/C> 2,494,746 1.10%
Insync Investments Pty Ltd <Weekley Super Fund No 1 A/C> 2,000,000 0.88%
Gravcon Pty Ltd 1,849,158 0.81%
Citicorp Nominees Pty Limited 1,605,473 0.71%
Mr William David Frank Bird 1,500,000 0.66%
Coin Superannuation Fund Pty Ltd <Coin Super A/C> 1,400,000 0.62%
Dr Roger Aston 1,371,376 0.60%
Mr Anthony Frederick Wallace Hyett 1,350,000 0.59%
Anne Pattison Pty Ltd <Aep No 3 A/C> 1,345,000 0.59%
Mr Peter Anastasiou & Mrs Kristine Patricia Anastasiou <Anastasiou Super Fund A/C> 1,332,187 0.59%
Mr Iain Chaney & Mrs Antonia Chaney <I & A Chaney Super Fund A/C> 1,235,270 0.54%
South Hong Nominees Pty Ltd <Hong Super Fund A/C> 1,200,000 0.53%
Fifty-Fifth Leprechaun Pty Ltd <The Andria A/C> 1,079,362 0.48%
Karma Wealth Pty Ltd <Lally Family Super Fund A/C> 1,050,000 0.46%
Inverarey Pty Ltd <The Kilchurn A/C> 1,050,000 0.46%
Karma Wealth Pty Ltd 1,000,000 0.44%

Profile

since

Note